Organigram Holdings Inc. OGI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
45/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About Organigram Holdings Inc.

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and … Full OGI analysis →

Key strengths

  • Operating Expense Control OpEx growth is controlled (score 0.60), demonstrating operating leverage.
  • Operating Leverage in Effect Operating leverage is evident (score 0.76), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 28.7th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.31), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
27
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OGI ranks in Drug Manufacturers - Specialty & Generic

Organigram Holdings Inc. ranks #41 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 45%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
37 Evotec SE EVO 47/100 Developing
38 Eton Pharmaceuticals, Inc. ETON 46/100 Developing
39 Cronos Group Inc. Common Share CRON 46/100 Developing
40 Tilray Brands, Inc. TLRY 45/100 Developing
41 Organigram Holdings Inc. OGI 45/100 Developing
42 Perrigo Company plc PRGO 43/100 Developing
43 Viatris Inc. VTRS 43/100 Developing
44 Intercure Ltd. INCR 42/100 Developing
45 TherapeuticsMD, Inc. TXMD 42/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How OGI scores on the Corporate Default defenses

Pricing Power

Score 27 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 63 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 40 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 52 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 57 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OGI's moat

What is Organigram Holdings Inc.'s moat score?

Organigram Holdings Inc. (OGI) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #41 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 45%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Cost Advantage (63/100) and its weakest is Pricing Power (27/100).

How does Organigram Holdings Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Organigram Holdings Inc. ranks #41 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Tilray Brands, Inc. (TLRY) at 45 just above it and Perrigo Company plc (PRGO) at 43 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Organigram Holdings Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Organigram Holdings Inc.?

The Corporate Default template measures 6 defenses, and OGI scores: Pricing Power (27), Cost Advantage (63), Customer Stickiness (40), Capital Efficiency (38), Resilience (52), Scale & Market Position (57). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000